Takehiro Tozuka

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Small Cell Lung Cancer

Brain Metastases

Top Venues

OncoTargets and therapy

Cancer medicine

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike
Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. Cancer medicine 13 (12) (2024)
Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike
Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. Cancer medicine 13 (12) (2024)
Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike
Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. Cancer medicine 13 (12) (2024)
Kakeru Hisakane, Takehiro Tozuka, Satoshi Takahashi, Namiko Taniuchi, Nobuhiko Nishijima, Kenichiro Atsumi, Tetsuya Okano, Masahiro Seike, Takashi Hirose
Platinum-combination chemotherapy with or without immune-checkpoint inhibitor in patients with postoperative recurrent non-small cell lung cancer previously treated with adjuvant platinum-doublet chemotherapy: A multicenter retrospective study. Thoracic cancer (2023)
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)
Kazuhito Misawa, Shinji Nakamichi, Hiroki Iida, Atsuhiro Nagano, Erika Mikami, Takehiro Tozuka, Masaru Matsumoto, Akihiko Miyanaga, Rintaro Noro, Kaoru Kubota, Hiroki Yamaguchi, Masahiro Seike
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report. OncoTargets and therapy 16 (2023)
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)
Takehiro Tozuka, Rintaro Noro, Akihiko Miyanaga, Shinji Nakamichi, Susumu Takeuchi, Masaru Matsumoto, Kaoru Kubota, Kazuo Kasahara, Masahiro Seike
Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer. Cancer medicine (2023)
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike
Remarkable Clinical Response of ALK -Rearranged/ TP53 -Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report. OncoTargets and therapy 16 (2023)
Kazuhito Misawa, Shinji Nakamichi, Hiroki Iida, Atsuhiro Nagano, Erika Mikami, Takehiro Tozuka, Masaru Matsumoto, Akihiko Miyanaga, Rintaro Noro, Kaoru Kubota, Hiroki Yamaguchi, Masahiro Seike
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report. OncoTargets and therapy 16 (2023)
Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka, Ryota Saito, Yosuke Kawashima, Fumiyoshi Ohyanagi, Takehiro Tozuka, Tsugitomi Ryosuke, Toshio Sakatani, Atsushi Horiike, Takahiro Yoshizawa, Masafumi Saiki, Yuichi Tambo, Junji Koyama, Masaki Kanazu, Keita Kudo, Yuko Tsuchiya-Kawano, Noriko Yanagitani, Makoto Nishio
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). Thoracic cancer (2022)
Takehiro Tozuka, Rintaro Noro, Masahiro Seike, Kazufumi Honda
Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability. Cancers 14 (18) (2022)
Anna Hayashi, Shinji Nakamichi, Yukako Nakayama, Atsuhiro Nagano, Erika Mikami, Natsuki Takano, Takehiro Tozuka, Masaru Matsumoto, Akihiko Miyanaga, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro Seike, Akihiko Gemma
Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report. OncoTargets and therapy 15 (2022)
Takehiro Tozuka, Satoru Kitazono, Hiroaki Sakamoto, Hiroshi Yoshida, Yoshiaki Amino, Shinya Uematsu, Takahiro Yoshizawa, Tsukasa Hasegawa, Ryo Ariyasu, Ken Uchibori, Noriko Yanagitani, Takeshi Horai, Masahiro Seike, Akihiko Gemma, Makoto Nishio
Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases. Thoracic cancer 11 (9) (2020)